Accelerating Discoveries Into Medicines
The Stanford Innovative Medicines Accelerator (IMA) seeks to accelerate the translation of Stanford research discoveries into new medicines while expanding our knowledge of human biology.
Get on the
At the IMA, we accelerate scientific breakthroughs at Stanford and help them find the speediest path to patients. With access to the world’s most celebrated biomedical science community coupled with our experienced drug discovery team, we help fast-track the prototyping of new medicines while also enabling patient-facing studies that inform the development of these medicines.
Think of the IMA as a navigation system along a super-highway, with on-ramps and off-ramps at critical stages of drug discovery and early development.
Shaping the Future of Medicines
Along this super-highway, it is the dedicated scientists of the IMA who facilitate the transformation of Stanford’s biomedical breakthroughs into game changing medicines. These scientists include individuals with immense industrial experience and diverse domain expertise ranging from high-throughput screening and medicinal chemistry to the prototyping of protein and gene therapies and the development of informative non-clinical models of complex diseases. They also include experts in clinical investigation and regulatory affairs.
At its core, every IMA project is led by a triumvirate of the faculty innovator, a senior member of the IMA scientific team, and a project manager who collaboratively shepherd the goal- and milestone-driven project through its various stages of validation and scaling.
Unlocking Stanford’s Innovations
We are on a mission to fulfill the promise of Stanford University to be more purposeful with the knowledge we create for the greater benefit of society. To act on this mission, we identify fundamental scientific breakthroughs made by our faculty and pressure test them to see if they can be turned into impactful medicines.
Our end goal is to bring the benefits of that research outside of Stanford through partnerships with external entities such as pharmaceutical companies, life science investors, fast-growing biotechs, or even fledgling startups that are resourced to deliver these advancements to patients worldwide.
Director, High-Throughput Screening
Director, Preclinical Pharmacology
Director, Protein Therapeutics
Director, Cell and Gene Therapies
Director, IMA Clinical and Translational Research Unit
Director, Medicinal Chemistry
APMAP inhibitors to enhance monoclonal antibody cancer therapies
Freeze-dried, nanoparticle-based COVID-19 vaccine
Click on a year to learn more.
Our Vision / Beginnings
Planning for Stanford’s Vision commences, and university leaders begin outlining a plan to turn more Stanford discoveries into new medicines
COVID-19 Starts to Spread Globally
Long-planned and fueled by the global pandemic, the IMA launches and focuses its early efforts on addressing COVID-19
Small molecule therapeutics pipeline initiated
The IMA launches first non-COVID RFP focused on developing new small molecule therapeutics
Protein therapeutics pipeline initiated
The IMA launches first non-COVID RFP for protein therapeutics
Patient-facing studies pipeline initiated
The IMA launches first non-COVID RFP for patient-facing studies
Cell and gene therapies pipeline initiated
The IMA launches first cell and gene therapies RFP